Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963)

Funda Meric-Bernstam; Randy F. Sweis; F. Stephen Hodi; Wells A. Messersmith; Robert H.I. Andtbacka; Matthew Ingham; Nancy Lewis; Xinhui Chen; Marc Pelletier; Xueying Chen; Jincheng Wu; Thomas W. Dubensky; Sarah M. McWhirter; Thomas Müller; Nitya Nair; Jason J. Luke

doi:10.1158/1078-0432.CCR-23-1170

Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963)

Funda Meric-Bernstam
, Randy F. Sweis
, F. Stephen Hodi
, Wells A. Messersmith
, Robert H.I. Andtbacka
, Matthew Ingham
, Nancy Lewis
, Xinhui Chen
, Marc Pelletier
, Xueying Chen
, Jincheng Wu
, Thomas W. Dubensky
, Sarah M. McWhirter
, Thomas Müller
, Nitya Nair
, Jason J. Luke

Investigational Cancer Therapeutics

Research output: Contribution to journal › Comment/debate › peer-review

12 Scopus citations

Abstract

In the original version of this article (1), author Thomas W. Dubensky is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the author contributions and disclosures have been updated as necessary. The authors regret this error.

Original language	English (US)
Pages (from-to)	2336
Number of pages	1
Journal	Clinical Cancer Research
Volume	29
Issue number	12
DOIs	https://doi.org/10.1158/1078-0432.CCR-23-1170
State	Published - Jun 15 2023

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/1078-0432.CCR-23-1170

Fingerprint

Dive into the research topics of 'Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963)'. Together they form a unique fingerprint.

Cite this

Meric-Bernstam, F., Sweis, R. F., Hodi, F. S., Messersmith, W. A., Andtbacka, R. H. I., Ingham, M., Lewis, N., Chen, X., Pelletier, M., Chen, X., Wu, J., Dubensky, T. W., McWhirter, S. M., Müller, T., Nair, N., & Luke, J. J. (2023). Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963). Clinical Cancer Research, 29(12), 2336. https://doi.org/10.1158/1078-0432.CCR-23-1170

Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963). / Meric-Bernstam, Funda; Sweis, Randy F.; Hodi, F. Stephen et al.
In: Clinical Cancer Research, Vol. 29, No. 12, 15.06.2023, p. 2336.

Research output: Contribution to journal › Comment/debate › peer-review

Meric-Bernstam, F, Sweis, RF, Hodi, FS, Messersmith, WA, Andtbacka, RHI, Ingham, M, Lewis, N, Chen, X, Pelletier, M, Chen, X, Wu, J, Dubensky, TW, McWhirter, SM, Müller, T, Nair, N & Luke, JJ 2023, 'Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963)', Clinical Cancer Research, vol. 29, no. 12, pp. 2336. https://doi.org/10.1158/1078-0432.CCR-23-1170

Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M et al. Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963). Clinical Cancer Research. 2023 Jun 15;29(12):2336. doi: 10.1158/1078-0432.CCR-23-1170

@article{4d2d9ce4b8004f7f9084d1fb6c8707d6,

title = "Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677{\textendash}688) DOI: 10.1158/1078-0432.CCR-21-1963)",

abstract = "In the original version of this article (1), author Thomas W. Dubensky is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the author contributions and disclosures have been updated as necessary. The authors regret this error.",

author = "Funda Meric-Bernstam and Sweis, \{Randy F.\} and Hodi, \{F. Stephen\} and Messersmith, \{Wells A.\} and Andtbacka, \{Robert H.I.\} and Matthew Ingham and Nancy Lewis and Xinhui Chen and Marc Pelletier and Xueying Chen and Jincheng Wu and Dubensky, \{Thomas W.\} and McWhirter, \{Sarah M.\} and Thomas M{\"u}ller and Nitya Nair and Luke, \{Jason J.\}",

note = "Publisher Copyright: {\textcopyright}2023 American Association for Cancer Research",

year = "2023",

month = jun,

day = "15",

doi = "10.1158/1078-0432.CCR-23-1170",

language = "English (US)",

volume = "29",

pages = "2336",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "12",

}

TY - JOUR

T1 - Erratum

T2 - Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963)

AU - Meric-Bernstam, Funda

AU - Sweis, Randy F.

AU - Hodi, F. Stephen

AU - Messersmith, Wells A.

AU - Andtbacka, Robert H.I.

AU - Ingham, Matthew

AU - Lewis, Nancy

AU - Chen, Xinhui

AU - Pelletier, Marc

AU - Chen, Xueying

AU - Wu, Jincheng

AU - Dubensky, Thomas W.

AU - McWhirter, Sarah M.

AU - Müller, Thomas

AU - Nair, Nitya

AU - Luke, Jason J.

PY - 2023/6/15

Y1 - 2023/6/15

N2 - In the original version of this article (1), author Thomas W. Dubensky is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the author contributions and disclosures have been updated as necessary. The authors regret this error.

AB - In the original version of this article (1), author Thomas W. Dubensky is mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the author contributions and disclosures have been updated as necessary. The authors regret this error.

UR - https://www.scopus.com/pages/publications/85163201359

UR - https://www.scopus.com/pages/publications/85163201359#tab=citedBy

U2 - 10.1158/1078-0432.CCR-23-1170

DO - 10.1158/1078-0432.CCR-23-1170

M3 - Comment/debate

C2 - 37309603

AN - SCOPUS:85163201359

SN - 1078-0432

VL - 29

SP - 2336

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 12

ER -

Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this